Menu
Search
|

Menu

Close
X

Ascendis Pharma A/S ASND.OQ (NASDAQ Stock Exchange Global Select Market)

114.89 USD
-1.22 (-1.05%)
As of Jul 19
Previous Close 116.11
Open 115.92
Volume 38,658
3m Avg Volume 80,146
Today’s High 117.14
Today’s Low 113.70
52 Week High 133.61
52 Week Low 53.29
Shares Outstanding (mil) 36.37
Market Capitalization (mil) 1,304.09
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.40 Mean rating from 10 analysts

KEY STATS

Revenue (mm, EUR)
FY19
5
FY18
11
FY17
2
FY16
5
EPS (EUR)
FY19
-1.237
FY18
-3.187
FY17
-3.683
FY16
-2.603
*Note: Units in Millions of Euro
**Note: Units in Euro

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.67
Price to Sales (TTM)
vs sector
367.07
7.92
Price to Book (MRQ)
vs sector
7.85
5.39
Price to Cash Flow (TTM)
vs sector
--
24.37
Total Debt to Equity (MRQ)
vs sector
0.00
14.56
LT Debt to Equity (MRQ)
vs sector
0.00
10.21
Return on Investment (TTM)
vs sector
-83.31
14.49
Return on Equity (TTM)
vs sector
-83.31
15.79

EXECUTIVE LEADERSHIP

Michael Wolff Jensen
Chairman of the Board, Senior Vice President, General Counsel, Since 2013
Salary: --
Bonus: --
Jan Moeller Mikkelsen
President, Chief Executive Officer, Director, Since 2007
Salary: --
Bonus: --
Scott Smith
Chief Financial Officer, Senior Vice President, Since 2016
Salary: --
Bonus: --
Lotte Soenderbjerg
Senior Vice President, Chief Administrative Officer, Since 2007
Salary: --
Bonus: --
Harald Rau
Senior Vice President, Chief Scientific Officer, Since 2007
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Tuborg Boulevard 5
HELLERUP     2900

Phone:

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. It is also using its TransCon technology platform to develop TransCon Parathyroid Hormone (TransCon PTH) for hypoparathyroidism, a rare endocrine disorder of calcium and phosphate metabolism.

SPONSORED STORIES